SETD2 and pelvic inflammatory disease: The results of the functional assays showed that the SETD2 mutations found in PID patients impair its enzymatic activity to catalyze trimethylation of the lysine residue at H3K36, providing additional support for the clinical relevance of SETD2 mutations, especially those associated with lymphopenia and immunoglobin defects, in PID patients.